Prostate cancer Archives

Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men

ASCO21: Novartis’ prostate cancer radiotherapy extends survival

https://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/

Market Access/ News/ News

NICE rejects J&J’s prostate cancer drug Erleada in initial guidance

Richard Staines Johnson & Johnson, market access, NICE, Prostate cancer 0 Comment

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone

NICE rejects J&J’s prostate cancer drug Erleada in initial guidance

https://pharmaphorum.com/news/nice-rejects-jjs-prostate-cancer-drug-erleada-in-initial-guidance/

Janssen J&J Johnson and Johnson pharmaceutical companies

News/ News/ Oncology

J&J decides against Erleada+Zytiga combination prostate cancer filing

Richard Staines cancer, Prostate cancer 0 Comment

Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators,

J&J decides against Erleada+Zytiga combination prostate cancer filing

https://pharmaphorum.com/news/jj-decides-against-erleadazytiga-combination-prostate-cancer-filing/

News/ News/ Oncology

Novartis’ radioligand therapy meets phase 3 prostate cancer trial target

Richard Staines Advanced Accelerator Applications, Endocyte, Oncology, Prostate cancer 0 Comment

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist

Novartis’ radioligand therapy meets phase 3 prostate cancer trial target

https://pharmaphorum.com/news/novartis-radioligand-therapy-meets-target-in-prostate-cacner/

Market Access/ News/ News

NICE says no to AZ’s Lynparza for prostate cancer

Phil Taylor AstraZeneca, HEOR, Lynparza, NHS, NICE, Oncology, PARP inhibitor, Prostate cancer, UK 0 Comment

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they

NICE says no to AZ’s Lynparza for prostate cancer

https://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/

Oncology/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Sharing experiences to level the healthcare playing field

Amanda Barrell BAME, clinical trials, diversity and inclusion, patient insights, Prostate cancer 0 Comment

Amanda Barrell speaks to Alfred Samuels on his experience of prostate cancer and diversifying clinical trials to include

Sharing experiences to level the healthcare playing field

https://pharmaphorum.com/views-analysis-oncology/sharing-experiences-to-level-the-healthcare-playing-field/

News/ News/ Oncology

Valirx eyes partnerships as first VAL201 study hits the mark

Phil Taylor clinical trial, Oncology, Prostate cancer, Valirx 0 Comment

Shares in UK biotech Valirx were up sharpy this morning after its lead drug VAL201 showed evidence of

Valirx eyes partnerships as first VAL201 study hits the mark

https://pharmaphorum.com/news/valirx-eyes-partnerships-as-first-val201-study-hits-the-mark/

News/ News/ Oncology

EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancer

Richard Staines AstraZeneca, cancer, ovarian cancer, Prostate cancer 0 Comment

AstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s

EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancer

https://pharmaphorum.com/news/az-grabs-twin-eu-approval-for-lynparza-in-prostate-and-ovarian-cancer-uses/

Stock brokers looking at computer screens, trading online.

News/ News/ News/ Oncology/ R&D

Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&D

Richard Staines cancer, CAR T, Funding, IPO, multiple myeloma, Poseida Therapeutics, Prostate cancer 0 Comment

California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last

Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&D

https://pharmaphorum.com/news/poseida-therapeutics/

Trending

Prostate cancer

Login